Not to be outdone by ongoing FTLD cohort studies underway mostly in Europe, U.S.-Canadian studies are now forging structured networks to track presymptomatic and symptomatic cases and to engage a panoply of funders and advocacy groups in a clinical trials initiative.
You might not think it possible to assemble large, longitudinal cohorts of loyal study subjects for rare dementias marked by apathy and emotional blunting. Think again—at the International Conference for Frontotemporal Dementia, researchers showed that they just did it.
Confirming hints from case reports, the Genetic FTD Initiative, a European-Canadian frontotemporal dementia network, shows which brain areas change long before tau, progranulin, and C9ORF72 mutation carriers become symptomatic.
Researchers detect aberrant methylation in genome regions that associate with late-onset AD.
Trophic factor may rejuvenate aging cells and protect neurons.
Term covers tauopathy in the absence of Aβ, regardless of cognitive state.
Researchers claim basic conclusions still sound.
Standardized scale to harmonize results from different imaging strategies.
Primates tolerate treatment with bispecific antibodies that smuggle anti-BACE1 across the blood-brain barrier.
Vancouver Frontotemporal Dementia Conference Shows Awakening Field First Data from GENFI1: Brain’s Insula Region Shrinks A Decade Before FTD German Network of 700 FTLD Patients Presents Baseline Data Meet the Artful Leftie: NIH Jump-Starts U.S.-Canadian ...
Scientific advances fire up researchers at FTD meeting in a dreary Vancouver.
Compound clears Phase 1 hurdle.
A drug that inhibits the sodium/potassium pump rescues a mouse model of the disease.
A protease previously linked to hyperphosphorylation of tau is now found to cleave the protein. The enzyme worsens tau pathology in transgenic mice.
A small Aβ fragment produced in healthy brains binds acetylcholine receptors and enhances synaptic plasticity and learning, while blocking the toxic effects of Aβ42.